Cargando…

In vivo metallophilic self-assembly of a light-activated anticancer drug

Self-assembling molecular drugs combine the easy preparation typical of small-molecule chemotherapy and the tumour-targeting properties of drug–nanoparticle conjugates. However, they require a supramolecular interaction that survives the complex environment of a living animal. Here we report that th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xue-Quan, Wang, Peiyuan, Ramu, Vadde, Zhang, Liyan, Jiang, Suhua, Li, Xuezhao, Abyar, Selda, Papadopoulou, Panagiota, Shao, Yang, Bretin, Ludovic, Siegler, Maxime A., Buda, Francesco, Kros, Alexander, Fan, Jiangli, Peng, Xiaojun, Sun, Wen, Bonnet, Sylvestre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322715/
https://www.ncbi.nlm.nih.gov/pubmed/37169984
http://dx.doi.org/10.1038/s41557-023-01199-w
_version_ 1785068819868286976
author Zhou, Xue-Quan
Wang, Peiyuan
Ramu, Vadde
Zhang, Liyan
Jiang, Suhua
Li, Xuezhao
Abyar, Selda
Papadopoulou, Panagiota
Shao, Yang
Bretin, Ludovic
Siegler, Maxime A.
Buda, Francesco
Kros, Alexander
Fan, Jiangli
Peng, Xiaojun
Sun, Wen
Bonnet, Sylvestre
author_facet Zhou, Xue-Quan
Wang, Peiyuan
Ramu, Vadde
Zhang, Liyan
Jiang, Suhua
Li, Xuezhao
Abyar, Selda
Papadopoulou, Panagiota
Shao, Yang
Bretin, Ludovic
Siegler, Maxime A.
Buda, Francesco
Kros, Alexander
Fan, Jiangli
Peng, Xiaojun
Sun, Wen
Bonnet, Sylvestre
author_sort Zhou, Xue-Quan
collection PubMed
description Self-assembling molecular drugs combine the easy preparation typical of small-molecule chemotherapy and the tumour-targeting properties of drug–nanoparticle conjugates. However, they require a supramolecular interaction that survives the complex environment of a living animal. Here we report that the metallophilic interaction between cyclometalated palladium complexes generates supramolecular nanostructures in living mice that have a long circulation time (over 12 h) and efficient tumour accumulation rate (up to 10.2% of the injected dose per gram) in a skin melanoma tumour model. Green light activation leads to efficient tumour destruction due to the type I photodynamic effect generated by the self-assembled palladium complexes, as demonstrated in vitro by an up to 96-fold cytotoxicity increase upon irradiation. This work demonstrates that metallophilic interactions are well suited to generating stable supramolecular nanotherapeutics in vivo with exceptional tumour-targeting properties. [Image: see text]
format Online
Article
Text
id pubmed-10322715
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103227152023-07-07 In vivo metallophilic self-assembly of a light-activated anticancer drug Zhou, Xue-Quan Wang, Peiyuan Ramu, Vadde Zhang, Liyan Jiang, Suhua Li, Xuezhao Abyar, Selda Papadopoulou, Panagiota Shao, Yang Bretin, Ludovic Siegler, Maxime A. Buda, Francesco Kros, Alexander Fan, Jiangli Peng, Xiaojun Sun, Wen Bonnet, Sylvestre Nat Chem Article Self-assembling molecular drugs combine the easy preparation typical of small-molecule chemotherapy and the tumour-targeting properties of drug–nanoparticle conjugates. However, they require a supramolecular interaction that survives the complex environment of a living animal. Here we report that the metallophilic interaction between cyclometalated palladium complexes generates supramolecular nanostructures in living mice that have a long circulation time (over 12 h) and efficient tumour accumulation rate (up to 10.2% of the injected dose per gram) in a skin melanoma tumour model. Green light activation leads to efficient tumour destruction due to the type I photodynamic effect generated by the self-assembled palladium complexes, as demonstrated in vitro by an up to 96-fold cytotoxicity increase upon irradiation. This work demonstrates that metallophilic interactions are well suited to generating stable supramolecular nanotherapeutics in vivo with exceptional tumour-targeting properties. [Image: see text] Nature Publishing Group UK 2023-05-11 2023 /pmc/articles/PMC10322715/ /pubmed/37169984 http://dx.doi.org/10.1038/s41557-023-01199-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Zhou, Xue-Quan
Wang, Peiyuan
Ramu, Vadde
Zhang, Liyan
Jiang, Suhua
Li, Xuezhao
Abyar, Selda
Papadopoulou, Panagiota
Shao, Yang
Bretin, Ludovic
Siegler, Maxime A.
Buda, Francesco
Kros, Alexander
Fan, Jiangli
Peng, Xiaojun
Sun, Wen
Bonnet, Sylvestre
In vivo metallophilic self-assembly of a light-activated anticancer drug
title In vivo metallophilic self-assembly of a light-activated anticancer drug
title_full In vivo metallophilic self-assembly of a light-activated anticancer drug
title_fullStr In vivo metallophilic self-assembly of a light-activated anticancer drug
title_full_unstemmed In vivo metallophilic self-assembly of a light-activated anticancer drug
title_short In vivo metallophilic self-assembly of a light-activated anticancer drug
title_sort in vivo metallophilic self-assembly of a light-activated anticancer drug
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322715/
https://www.ncbi.nlm.nih.gov/pubmed/37169984
http://dx.doi.org/10.1038/s41557-023-01199-w
work_keys_str_mv AT zhouxuequan invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT wangpeiyuan invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT ramuvadde invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT zhangliyan invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT jiangsuhua invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT lixuezhao invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT abyarselda invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT papadopouloupanagiota invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT shaoyang invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT bretinludovic invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT sieglermaximea invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT budafrancesco invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT krosalexander invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT fanjiangli invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT pengxiaojun invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT sunwen invivometallophilicselfassemblyofalightactivatedanticancerdrug
AT bonnetsylvestre invivometallophilicselfassemblyofalightactivatedanticancerdrug